These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Adverse events associated with antiangiogenic agents in combination with cytotoxic chemotherapy in metastatic colorectal cancer and their management. Cartwright TH Clin Colorectal Cancer; 2013 Jun; 12(2):86-94. PubMed ID: 23562587 [TBL] [Abstract][Full Text] [Related]
8. Managing patients with metastatic colorectal cancer on bevacizumab. Lemmens L; Claes V; Uzzell M Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic strategies using VEGF inhibitors in colorectal cancer]. Boige V; Malka D; Ducreux M Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667 [TBL] [Abstract][Full Text] [Related]
10. [Anti-angiogenic therapy for gastrointestinal tumours]. Graepler F; Gregor M; Lauer UM Z Gastroenterol; 2005 Mar; 43(3):317-29. PubMed ID: 15765305 [TBL] [Abstract][Full Text] [Related]
11. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. Manegold C Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923 [TBL] [Abstract][Full Text] [Related]
19. The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma. Shah MA Clin Adv Hematol Oncol; 2014 Apr; 12(4):239-46. PubMed ID: 25003353 [TBL] [Abstract][Full Text] [Related]